FDA Approves Pfizer and Arvinas Breast Cancer Drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2026
0mins
Source: Newsfilter
- New Drug Approval: The FDA has approved Veppanu, a breast cancer drug developed by Pfizer and Arvinas, specifically designed for advanced patients with a specific genetic mutation, marking a significant advancement in treatment options.
- Clinical Trial Results: In a late-stage trial involving 624 participants, Veppanu demonstrated a significant extension in the duration of patients' survival without disease progression compared to the traditional hormone therapy fulvestrant, indicating competitive efficacy.
- Market Outlook: Arvinas CEO Randy Teel stated that Veppanu provides a much-needed treatment option for stage-4 breast cancer patients, with plans to announce a commercialization deal in the coming weeks to clarify pricing strategies.
- Companion Test Approval: The FDA also approved the Guardant360 CDx blood test to identify patients carrying the ESR1 mutation, ensuring the drug's targeted application and enhancing treatment effectiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 23.670
Low
24.00
Averages
28.56
High
35.00
Current: 23.670
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Stock Declines Ahead of Earnings Report
- Stock Performance Decline: Pfizer (PFE) fell by 2.75% to $24.04 in the latest trading session, trailing the S&P 500's 0.1% daily loss, indicating market concerns regarding its future performance.
- Earnings Report Outlook: Pfizer is set to announce its earnings on August 4, 2026, with an expected EPS of $0.68, reflecting a year-over-year decline of 12.82%, while revenue is projected at $14.4 billion, a 1.71% drop from the previous year, highlighting profitability challenges.
- Analyst Ratings Stability: Currently, Pfizer holds a Zacks Rank of 3 (Hold), indicating a neutral outlook from analysts, and while estimate revisions have remained stagnant, this could impact investor confidence in the stock.
- Valuation Appeal: With a forward P/E ratio of 8.28, significantly lower than the industry average of 15.31, Pfizer's stock may be undervalued, attracting value investors, especially as it ranks in the top 39% of the large-cap pharmaceuticals sector.
See More
Tech Stocks Retreat Amid Market Volatility
- Market Volatility: The S&P 500 slightly rose on Friday, capping a volatile week, while semiconductor stocks like Micron and Nvidia fell, reflecting market concerns over OpenAI's potential IPO delay.
- Nike's Stock Resilience: Despite KeyBanc downgrading Nike to a hold-equivalent rating, the stock saw modest gains, with analysts highlighting ongoing weakness in China but expressing optimism about the new CFO's appointment, which could lead to necessary cleanup actions.
- Honeywell Spin-off Outlook: Honeywell's shares dipped ahead of the spin-off of its Aerospace division, with RBC Capital Markets initiating coverage with a buy rating and a $300 price target, indicating a potential 35% upside, suggesting the aerospace sector is undervalued.
- Investor Sentiment: The Investing Club maintains its stance on Nike, viewing the next quarter as a critical moment that could determine the company's recovery trajectory amidst ongoing challenges.
See More
Trump Administration Narrows FDA Commissioner Candidates
- Candidate List Narrowed: The Trump administration has reduced the list of FDA commissioner candidates to three, including senior Pentagon health official Stephen Ferrara, oncologist Jeffrey Vacirca, and Heidi Overton, who has served as Deputy Assistant to the President for Domestic Policy since January 2025, indicating a focused approach to FDA leadership.
- Ferrara as Front-Runner: With his previous roles as chief medical officer for the Navy and CIA, Ferrara is seen as the favorite, which could significantly influence future FDA policy directions and regulatory decisions.
- Background on Vacancy: The commissioner position has been vacant since May 12, when Marty Makary resigned amid disagreements with the administration, a situation that may affect the FDA's decision-making efficiency and public trust.
- Healthcare Industry Dynamics: Amid this backdrop, major pharmaceutical companies like Pfizer and Merck continue to accelerate M&A activities, demonstrating resilience and growth potential in the healthcare sector despite policy uncertainties.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
Comparative Growth Strategies of AbbVie and Pfizer
- AbbVie's Growth Potential: AbbVie reported approximately $61.2 billion in revenue for FY 2025, reflecting an 8.7% increase, with a net income of about $4.3 billion, indicating that its strategy focusing on high-margin specialty medicines is effective despite biosimilar competition pressures.
- Pfizer's Diversification Strategy: Pfizer generated nearly $62.6 billion in revenue for FY 2025, a slight decline of 1.6%, but net income reached $7.8 billion, showcasing its efforts to diversify through acquisitions and expand its vaccine product lines to mitigate patent expirations, particularly in oncology.
- Patent Risks and Market Competition: AbbVie faces significant patent risks with core products like Humira, compounded by pricing pressures from the Inflation Reduction Act, potentially leading to revenue declines, while Pfizer is navigating a patent cliff and intense competition from rivals in the vaccine market.
- Future Outlook and Investor Confidence: AbbVie is expected to see net income soar to $14.6 billion in FY 2026, while Pfizer's net income is projected to increase by 40% to over $11 billion, although both companies will rely on FDA decisions and new product launches to sustain long-term growth.
See More
Dividend Investment Comparison: AbbVie vs. Pfizer
- Financial Performance Comparison: AbbVie reported nearly $61.2 billion in revenue for FY 2025, an 8.7% increase, with a net income of approximately $4.3 billion, showcasing strong growth potential in high-margin specialty medicines; in contrast, Pfizer's revenue was about $62.6 billion, a slight decline of 1.6%, yet it achieved a net income close to $7.8 billion, reflecting ongoing efforts in vaccine and drug development.
- Market Risk Analysis: AbbVie faces significant risks from patent expirations and biosimilar competition, particularly threatening Humira's market position, while needing to successfully integrate the acquisition of Apogee Therapeutics to meet growth targets; Pfizer is also approaching a patent cliff with several blockbuster drugs losing exclusivity, compounded by high debt levels and competitive pressures.
- Future Growth Expectations: AbbVie's net income is projected to soar to $14.6 billion by 2026, with sales growing to $67.2 billion, driven by successful launches of new products like Skyrizi and Rinvoq; Pfizer's net income is expected to jump by 40% to over $11 billion, with sales slightly increasing to $61.7 billion, although future sales may decline due to expiring patents.
- Investment Valuation Assessment: AbbVie has a forward P/E ratio of 16.6x and a P/S ratio of 6.8x, indicating investor confidence in its future earnings; Pfizer's lower forward P/E of 8.2x and P/S ratio of 2.2x suggest a lower current valuation, reflecting market uncertainty about its growth prospects.
See More
Pfizer Stock Declines Ahead of Earnings Report
- Stock Performance Decline: Pfizer (PFE) fell by 2.75% to $24.04 in the latest trading session, trailing the S&P 500's 0.1% daily loss, indicating market concerns regarding its future performance.
- Earnings Report Outlook: Pfizer is set to announce its earnings on August 4, 2026, with an expected EPS of $0.68, reflecting a year-over-year decline of 12.82%, while revenue is projected at $14.4 billion, a 1.71% drop from the previous year, highlighting profitability challenges.
- Analyst Ratings Stability: Currently, Pfizer holds a Zacks Rank of 3 (Hold), indicating a neutral outlook from analysts, and while estimate revisions have remained stagnant, this could impact investor confidence in the stock.
- Valuation Appeal: With a forward P/E ratio of 8.28, significantly lower than the industry average of 15.31, Pfizer's stock may be undervalued, attracting value investors, especially as it ranks in the top 39% of the large-cap pharmaceuticals sector.
See More
Tech Stocks Retreat Amid Market Volatility
- Market Volatility: The S&P 500 slightly rose on Friday, capping a volatile week, while semiconductor stocks like Micron and Nvidia fell, reflecting market concerns over OpenAI's potential IPO delay.
- Nike's Stock Resilience: Despite KeyBanc downgrading Nike to a hold-equivalent rating, the stock saw modest gains, with analysts highlighting ongoing weakness in China but expressing optimism about the new CFO's appointment, which could lead to necessary cleanup actions.
- Honeywell Spin-off Outlook: Honeywell's shares dipped ahead of the spin-off of its Aerospace division, with RBC Capital Markets initiating coverage with a buy rating and a $300 price target, indicating a potential 35% upside, suggesting the aerospace sector is undervalued.
- Investor Sentiment: The Investing Club maintains its stance on Nike, viewing the next quarter as a critical moment that could determine the company's recovery trajectory amidst ongoing challenges.
See More
Trump Administration Narrows FDA Commissioner Candidates
- Candidate List Narrowed: The Trump administration has reduced the list of FDA commissioner candidates to three, including senior Pentagon health official Stephen Ferrara, oncologist Jeffrey Vacirca, and Heidi Overton, who has served as Deputy Assistant to the President for Domestic Policy since January 2025, indicating a focused approach to FDA leadership.
- Ferrara as Front-Runner: With his previous roles as chief medical officer for the Navy and CIA, Ferrara is seen as the favorite, which could significantly influence future FDA policy directions and regulatory decisions.
- Background on Vacancy: The commissioner position has been vacant since May 12, when Marty Makary resigned amid disagreements with the administration, a situation that may affect the FDA's decision-making efficiency and public trust.
- Healthcare Industry Dynamics: Amid this backdrop, major pharmaceutical companies like Pfizer and Merck continue to accelerate M&A activities, demonstrating resilience and growth potential in the healthcare sector despite policy uncertainties.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
Comparative Growth Strategies of AbbVie and Pfizer
- AbbVie's Growth Potential: AbbVie reported approximately $61.2 billion in revenue for FY 2025, reflecting an 8.7% increase, with a net income of about $4.3 billion, indicating that its strategy focusing on high-margin specialty medicines is effective despite biosimilar competition pressures.
- Pfizer's Diversification Strategy: Pfizer generated nearly $62.6 billion in revenue for FY 2025, a slight decline of 1.6%, but net income reached $7.8 billion, showcasing its efforts to diversify through acquisitions and expand its vaccine product lines to mitigate patent expirations, particularly in oncology.
- Patent Risks and Market Competition: AbbVie faces significant patent risks with core products like Humira, compounded by pricing pressures from the Inflation Reduction Act, potentially leading to revenue declines, while Pfizer is navigating a patent cliff and intense competition from rivals in the vaccine market.
- Future Outlook and Investor Confidence: AbbVie is expected to see net income soar to $14.6 billion in FY 2026, while Pfizer's net income is projected to increase by 40% to over $11 billion, although both companies will rely on FDA decisions and new product launches to sustain long-term growth.
See More
Dividend Investment Comparison: AbbVie vs. Pfizer
- Financial Performance Comparison: AbbVie reported nearly $61.2 billion in revenue for FY 2025, an 8.7% increase, with a net income of approximately $4.3 billion, showcasing strong growth potential in high-margin specialty medicines; in contrast, Pfizer's revenue was about $62.6 billion, a slight decline of 1.6%, yet it achieved a net income close to $7.8 billion, reflecting ongoing efforts in vaccine and drug development.
- Market Risk Analysis: AbbVie faces significant risks from patent expirations and biosimilar competition, particularly threatening Humira's market position, while needing to successfully integrate the acquisition of Apogee Therapeutics to meet growth targets; Pfizer is also approaching a patent cliff with several blockbuster drugs losing exclusivity, compounded by high debt levels and competitive pressures.
- Future Growth Expectations: AbbVie's net income is projected to soar to $14.6 billion by 2026, with sales growing to $67.2 billion, driven by successful launches of new products like Skyrizi and Rinvoq; Pfizer's net income is expected to jump by 40% to over $11 billion, with sales slightly increasing to $61.7 billion, although future sales may decline due to expiring patents.
- Investment Valuation Assessment: AbbVie has a forward P/E ratio of 16.6x and a P/S ratio of 6.8x, indicating investor confidence in its future earnings; Pfizer's lower forward P/E of 8.2x and P/S ratio of 2.2x suggest a lower current valuation, reflecting market uncertainty about its growth prospects.
See More
